Aspen Pharmacare Holdings Limited (JSE: APN) expects FY26 normalised headline earnings per share from continuing operations to increase 19%-24% to 784.4-817.4 cents after second-half EBITDA growth of more than 45% reversed a difficult first half. The pharmaceutical group ended June with approximately R0.8 billion of net cash following completion of its R28 billion APAC divestment and R500 million of share repurchases.
Normalised EBITDA from continuing operations is expected between R7.46 billion and R7.81 billion, representing growth of 7%-12% from R6.97 billion. The recovery is particularly notable because normalised headline earnings from continuing operations had been down 25% during the first half, forcing a much stronger second-half performance to achieve the full-year outcome.
Aspen shares closed at R147.63 on August 21, up 2.78%, suggesting investors responded positively to the combination of better operating momentum and a substantially stronger balance sheet.
How did Aspen reverse a 25% first-half earnings decline?
Management said achieving its full-year EBITDA guidance required second-half normalised EBITDA growth of more than 45% from the comparable H2 FY25 figure of R2.565 billion. That threshold was reached, allowing the group to move from a 25% first-half decline in normalised headline earnings per share to double-digit full-year growth on a constant-currency basis.
Commercial Pharmaceuticals was the main driver. The segment delivered mid-single-digit revenue growth and early-double-digit normalised EBITDA growth at constant exchange rates, while Manufacturing also produced normalised EBITDA ahead of FY25.
The South African rand worked against the reported result because it strengthened against several of Aspen’s major trading currencies. That means the underlying operating recovery was stronger in constant-currency terms than the reported numbers alone imply.
Why is the R28 billion APAC divestment central to Aspen’s new financial profile?
The disposal generated R28 billion of gross proceeds and a R2.4 billion profit on sale. More strategically, it transformed Aspen’s leverage position sufficiently for the company to finish FY26 with approximately R0.8 billion of net cash even after spending R500 million on share buybacks.
That is a significant change for a pharmaceutical group that has historically carried substantial acquisition-related debt. Moving into net cash reduces interest expense and gives Aspen more flexibility around manufacturing investment, commercial expansion, additional capital returns and future transactions.
Management expects lower interest costs following the disposal to become another earnings tailwind in FY27. The APAC transaction therefore changes not only the asset portfolio but also the financial architecture supporting the remaining business.
Why are reported HEPS falling even though underlying earnings are growing?
This is where the FY26 earnings statement becomes more nuanced. Total normalised headline earnings per share are expected to increase 7%-12% to 1,129.8-1,182.6 cents, but statutory headline earnings per share are expected to decline 19%-24% to 602.0-641.6 cents.
The difference is driven partly by R2.3 billion of restructuring costs associated with efficiency and value-enhancement programmes. Those expenses reduce statutory HEPS even though Aspen expects the programmes to support future operational performance.
EPS tells yet another story. It is expected to swing to 550-620 cents from a loss of 243.9 cents because the R2.4 billion profit on the APAC disposal and lower impairment charges support statutory earnings. Aspen also recorded R2.3 billion of intangible-asset impairments, reflecting higher discount rates.
Investors therefore need to separate recurring operations, restructuring charges, asset-sale profits and impairments rather than relying on any single earnings measure.
What does generic semaglutide add to Aspen’s FY27 growth options?
Aspen received Health Canada approval for its generic injectable semaglutide product, although commercial timing depends on active pharmaceutical ingredient availability from Dr. Reddy’s Laboratories Limited.
That creates meaningful optionality because semaglutide is one of the most commercially important pharmaceutical molecules globally. Approval alone does not establish launch timing, market share or profitability, particularly when API supply is a constraint, but it gives Aspen access to a potentially significant category.
The company also commenced commercialisation of its human insulin manufacturing contract in May after approval from the South African Health Products Regulatory Authority. Together, those developments give Manufacturing additional growth avenues beyond simply improving utilisation at existing facilities.
Why could FY27 look financially cleaner than FY26?
The reshaping of Aspen’s sterile finished-dose manufacturing facilities in France and South Africa is nearing completion, with early efficiency benefits already visible in H2 FY26. Management expects further EBITDA recovery from those facilities in FY27.
Free cash flow excluding dividends is expected to exceed R3.7 billion for FY26, supported by cash conversion above the group’s 100% target, lower capital spending and improved working capital. A net-cash balance sheet should amplify the value of that cash generation through reduced financing expense.
The September 2 audited results will provide the full detail, but the trading statement already shows why Aspen shares responded positively. The group has moved from a 25% first-half underlying earnings decline to full-year growth, sold APAC for R28 billion and finished with net cash. The central FY27 question is whether that financial reset can now produce sustained earnings growth without another large portfolio transaction.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
